Sir Peter MacCallum Department of Oncology - Research Publications

Permanent URI for this collection

http://hdl.handle.net/11343/274

Filters

2014 - 2017 2
2
Reset filters

Settings
Statistics
Citations
Author: John, Thomas × Author: Solomon, Benjamin × End date: 2019 × Start date: 2014 ×

Search Results

Now showing 1 - 2 of 2
  • Item
    Thumbnail Image
    Treatment of ALK-rearranged non- small cell lung cancer: A review of the landscape and approach to emerging patterns of treatment resistance in the Australian context
    Itchins, M ; Chia, PL ; Hayes, SA ; Howell, VM ; Gill, AJ ; Cooper, WA ; John, T ; Mitchell, P ; Millward, M ; Clarke, SJ ; Solomon, B ; Pavlakis, N (WILEY, 2017-08)
    Since the identification of anaplastic lymphoma kinase (ALK) gene rearrangements in non-small cell lung cancer (NSCLC) in 2005, the treatment of ALK-rearranged NSCLC (ALK+ NSCLC) has evolved at a rapid pace. This molecularly distinct subset of NSCLC has uniquely important biology, clinicopathologic features and mechanisms of drug resistance which impact on the choice of treatment for a patient with this disease. There are multiple ALK tyrosine kinase inhibitors now available in clinical practice with efficacy data continuing to emerge and guide the optimal treatment algorithm. A detailed search of medical databases and clinical trial registries was conducted to capture all relevant articles on this topic enabling an updated detailed overview of the landscape of management of ALK-rearranged NSCLC.
  • Item
    Thumbnail Image
    A critical re-assessment of DNA repair gene promoter methylation in non-small cell lung carcinoma
    Do, H ; Wong, NC ; Murone, C ; John, T ; Solomon, B ; Mitchell, PL ; Dobrovic, A (NATURE PORTFOLIO, 2014-02-26)
    DNA repair genes that have been inactivated by promoter methylation offer potential therapeutic targets either by targeting the specific repair deficiency, or by synthetic lethal approaches. This study evaluated promoter methylation status for eight selected DNA repair genes (ATM, BRCA1, ERCC1, MGMT, MLH1, NEIL1, RAD23B and XPC) in 56 non-small cell lung cancer (NSCLC) tumours and 11 lung cell lines using the methylation-sensitive high resolution melting (MS-HRM) methodology. Frequent methylation in NEIL1 (42%) and infrequent methylation in ERCC1 (2%) and RAD23B (2%) are reported for the first time in NSCLC. MGMT methylation was detected in 13% of the NSCLCs. Contrary to previous studies, methylation was not detected in ATM, BRCA1, MLH1 and XPC. Data from The Cancer Genome Atlas (TCGA) was consistent with these findings. The study emphasises the importance of using appropriate methodology for accurate assessment of promoter methylation.